Stefan Huttenlocher1, Lena Sehmisch1, Steven E Schild2, Oliver Blank3, Dagmar Hornung4, Dirk Rades5. 1. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany. 2. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A. 3. CyberKnife Centre Northern Germany, Güstrow, Germany. 4. Department of Radiation Oncology, University Medical Center Eppendorf, Hamburg, Germany. 5. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany rades.dirk@gmx.net.
Abstract
BACKGROUND/AIM: To develop a tool for estimating the risk of developing new cerebral lesions in 69 melanoma patients receiving radiosurgery for 1-3 cerebral metastases. PATIENTS AND METHODS: Ten factors were investigated: lactate dehydrogenase (LDH), radiosurgery dose, age, gender, performance status, maximum diameter, location and number of cerebral lesions, extra-cranial spread, time between melanoma diagnosis and radiosurgery. Two factors, number of lesions and extra-cranial spread, were included in the tool. Scoring points were achieved by dividing the 6-month rate of freedom from new cerebral lesions by 10. RESULTS: Sum scores were 9, 11, 12 or 14 points. Six-month rates of freedom from new brain metastases were 28%, 63%, 59% and 92% (p=0.002). Three prognostic groups were designed: A (9 points), B (11-12 points) and C (14 points). Freedom from new cerebral lesion rates were 28%, 60% and 92% (p<0.001). CONCLUSION: Group A and B patients should be considered for additional whole-brain radiotherapy (WBRT). Copyright
BACKGROUND/AIM: To develop a tool for estimating the risk of developing new cerebral lesions in 69 melanomapatients receiving radiosurgery for 1-3 cerebral metastases. PATIENTS AND METHODS: Ten factors were investigated: lactate dehydrogenase (LDH), radiosurgery dose, age, gender, performance status, maximum diameter, location and number of cerebral lesions, extra-cranial spread, time between melanoma diagnosis and radiosurgery. Two factors, number of lesions and extra-cranial spread, were included in the tool. Scoring points were achieved by dividing the 6-month rate of freedom from new cerebral lesions by 10. RESULTS: Sum scores were 9, 11, 12 or 14 points. Six-month rates of freedom from new brain metastases were 28%, 63%, 59% and 92% (p=0.002). Three prognostic groups were designed: A (9 points), B (11-12 points) and C (14 points). Freedom from new cerebral lesion rates were 28%, 60% and 92% (p<0.001). CONCLUSION: Group A and B patients should be considered for additional whole-brain radiotherapy (WBRT). Copyright
Authors: Dirk Rades; Oliver Blanck; Mai Trong Khoa; Pham VAN Thai; Nguyen Quang Hung; Liesa Dziggel; Steven E Schild Journal: In Vivo Date: 2018 Mar-Apr Impact factor: 2.155
Authors: Imran H Chowdhury; Eric Ojerholm; Matthew T McMillan; Denise Miller; James D Kolker; Goldie Kurtz; Jay F Dorsey; Suneel N Nagda; Geoffrey A Geiger; Steven Brem; Donald M O'Rourke; Eric L Zager; Tara Gangadhar; Lynn Schuchter; John Y K Lee; Michelle Alonso-Basanta Journal: Radiat Oncol Date: 2015-12-01 Impact factor: 3.481